SPG7 anticorps (N-Term)
Aperçu rapide pour SPG7 anticorps (N-Term) (ABIN5515659)
Antigène
Voir toutes SPG7 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Séquence
- LWQLLGGTFY FNTSRLKQKN KEKDKSKGKA PEEDEEERRR RERDDQMYRE
-
Purification
- Affinity purified
-
Immunogène
- The immunogen is a synthetic peptide directed towards the N terminal region of human SPG7
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
- SPG7 (Spastic Paraplegia 7 (SPG7))
-
Autre désignation
- SPG7
-
Sujet
-
This gene encodes a mitochondrial metalloprotease protein that is a member of the AAA family. Members of this protein family share an ATPase domain and have roles in diverse cellular processes including membrane trafficking, intracellular motility, organelle biogenesis, protein folding, and proteolysis. Mutations in this gene cause autosomal recessive spastic paraplegia 7. Two transcript variants encoding distinct isoforms have been identified.
Alias Symbols: CAR, PGN, CMAR, SPG5C
Protein Size: 489 -
ID gène
- 6687
-
NCBI Accession
- NM_003119, NP_003110
Antigène
-